Molly Li, MBBS, discusses selecting between HER2-directed TKIs and antibody-drug conjugates in first-line HER2-mutant NSCLC.
Molly Li, MBBS
Advertisement
Articles by Molly Li, MBBS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Elfetabart Drozuntecan Elicits 70% ORR Across Lines of Therapy in SCLC
2
SERENA-4 Misses Primary PFS End Point With Camizestrant Plus Palbociclib in First-Line ER+ Advanced Breast Cancer
3
Dibotatug Is Safe and Yields Durable Responses in Large Granular Lymphocytic Leukemia
4
Extended-Interval Tarlatamab Yields Comparable Exposure, Survival to Q2W Dose in Previously Treated SCLC
5